Slovakia is a compact but strategically important clinical trial market in Central Europe.
With a population of 5.5 million, 44 state hospitals, full CTIS integration and EU membership since 2004, Slovakia offers sponsors a strong combination of regulatory credibility, patient access and operational efficiency.
Its clinical research activity is especially relevant across oncology, cardiovascular disease, neurology, endocrinology, diabetes, respiratory disease, rare diseases and medical devices.
For sponsors, Slovakia is valuable because it sits inside the Central European research corridor. Bratislava is only 60 km from Vienna, giving the country an unusual mix of CEE cost structure, EU quality standards, strong academic hospitals and direct access to Western European sponsor infrastructure.